Göteborg, Sweden-based Getinge acquired the biosurgery unit, which makes soft tissue reinforcement devices, in the $680 million deal for Atrium back in 2011. Today Getinge said it agreed to sell the business, which at $14.2 million in 2017 sales (SEK 128 million) is a relatively small segment, to SeCQure parent HJ Capital 1.
The deal for the biosurg business, Getinge’s only general surgery offering, covers all assets and liabilities except for mesh liability claims and associated insurance claims, the company said. The deal is expected to close during the fourth quarter, with no material impact on Getinge’s books.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.